Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Genomic Valley Biotech (BOM:539206) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Genomic Valley Biotech 9-Day RSI Related Terms
BOM:539206 vs VRTX, REGN, RVMD: 9-Day RSI Comparison
For the Biotechnology subindustry, Genomic Valley Biotech's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomic Valley Biotech 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Genomic Valley Biotech's 9-Day RSI falls into.
Genomic Valley Biotech (BOM:539206) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomic Valley Biotech (BOM:539206) has a 9-Day RSI of 57.06 as of Aug. 25, 2026. According to the industry distribution chart, Genomic Valley Biotech ranks #928 out of 1422 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Genomic Valley Biotech's 9-Day RSI too high?
Genomic Valley Biotech's current 9-Day RSI is 57.06. The Biotechnology industry median 9-Day RSI is 51.53. Genomic Valley Biotech's value of 57.06 is 10.7% above this industry median. Based on the distribution chart, Genomic Valley Biotech ranks #928 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genomic Valley Biotech has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomic Valley Biotech ranks #928 out of 1422 companies for 9-Day RSI. This places Genomic Valley Biotech in the lower half of its industry. The industry median 9-Day RSI is 51.53. Genomic Valley Biotech's value of 57.06 is 10.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 51.53, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomic Valley Biotech's current 9-Day RSI of 57.06 is 10.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 51.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomic Valley Biotech's current 9-Day RSI is 57.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.78, compared to a current price of ₹30.40 — trading 137.9% above its estimated fair value. The current 9-Day RSI is 57.06 and 10.7% above the Biotechnology industry median of 51.53. Genomic Valley Biotech's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current 9-Day RSI is 57.06 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?
Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued.
The current stock price of ₹30.40 is trading 137.9% above its estimated GF Value™ of ₹12.78.
GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.
Key valuation signals for BOM:539206:
9-Day RSI: 57.06
GF Value™: ₹12.78 vs. price of ₹30.40 (137.9% above fair value)
Industry Position: 10.7% above the Biotechnology median (#928 of 1422)
No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
58GF Score
Get the complete analysis for BOM:539206
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539206 has been successfully added to your 
